Treatment Naïve and Treatment Experienced

HIV Coinfection

Sofosbuvir in HCV-HIV Coinfection & HCV GT 1,2,3
PHOTON-1 Trial

Sulkowski MS, et al. JAMA. 2014;312:353-61.

Sofosbuvir and Ribavirin for HCV-HIV Coinfection
PHOTON-1 Trial: Study Features

PHOTON-1 Trial: Features

- **Design**: Open-label, nonrandomized, uncontrolled, phase 3 trial using sofosbuvir + ribavirin in HCV-HIV coinfection and HCV GT 1, 2, or 3
- **Setting**: 34 treatment centers in United States and Puerto Rico
- **Entry Criteria**
  - HIV coinfection; HCV Genotype 1, 2, or 3
  - Treatment naïve (GT 1,2,3) or treatment experienced (GT 2,3)
  - On antiretroviral therapy with HIV RNA ≤ 50 copies/ml and CD4 ≥ 200 or not on antiretroviral therapy and CD4 ≥ 500
  - Compensated cirrhosis permitted (<20% total patients)
- **Patient Characteristics**
  - N = 223 HCV-HIV coinfected patients
  - On ARV Rx: GT1 (98%); GT 2/3 naive (90%); GT 2/3 experienced (95%)
- **Primary End-Points**
  - Efficacy (SVR12), safety, and impact on HIV

Source: Sulkowski MS, et al. JAMA. 2014;312:353-61.

Sofosbuvir and Ribavirin for HCV-HIV Coinfection
PHOTON-1 Trial: Participants

	Treatment Naive		Treatment Experienced
	GT 1 (n=114)	GT 2 or 3 (n=68)	GT 2 or 3 (n=41)
Age, mean (range)	48 (25-70)	49 (24-71)	54 (34-68)
Male, %	82%	81%	90%
Black, %	32%	12%	17%
IL28B CC genotype, %	27%	37%	49%
Cirrhosis, %	4%	10%	24%
On ART[§], %	98%	90%	95%
CD4 count, cells/mm^3, median	581	562	579

[§]Tenofovir-emtricitabine plus [efavirenz, r-atazanavir, r-darunavir, raltegravir, rilpivirine, or other]

Source: Sulkowski MS, et al. JAMA. 2014;312:353-61.

Sofosbuvir and Ribavirin for HCV-HIV Coinfection
PHOTON-1 Trial: Treatment Arms



Drug Dosing

Sofosbuvir: 400 mg once daily

Ribavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg

Source: Sulkowski MS, et al. JAMA. 2014;312:353-61.

Sofosbuvir and Ribavirin for HCV-HIV Coinfection
PHOTON-1 Trial: Results

PHOTON-1: SVR 12 with Sofosbuvir + RBV x 12-24 weeks



Source: Sulkowski MS, et al. JAMA. 2014;312:353-61.

Hepatitis web study

Sofosbuvir and Ribavirin for HCV-HIV Coinfection
PHOTON-1 Trial: Conclusions

Conclusions and Relevance: “In this open-label, nonrandomized, uncontrolled study, patients with HIV who were coinfected with HCV genotype 1, 2, or 3 who received the oral, interferon-free combination of sofosbuvir and ribavirin for 12 or 24 weeks had high rates of SVR12. Further studies of this oral regimen in diverse populations of coinfected patients are warranted.”

Source: Sulkowski MS, et al. JAMA. 2014;312:353-61.

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online

www.hepatitisc.uw.edu

Hepatitis Web Study

http://depts.washington.edu/hepstudy/

Funded by a grant from the Centers for Disease Control and Prevention.

Hepatitis web study